Radionuclide bone scan in initial staging of breast cancer.

Tunis Med

Service de Médecine Nucléaire, Hôpital Sahloul-Sousse-Tunisie.

Published: March 2003

Radionuclide bone scans of 100 patients with newly diagnosed breast cancer were retrospectively analysed. The number and topography of increased area of uptake were noted. Diagnosis criterion was defined by at least four foci of increased uptake, outside peripheral articular joints. In case of a number between one and three, the result was considered doubtful and radionuclide bone scan was confronted to available standard X Rays or/and radionuclide bone scan follow-up. Correlations of radionuclide bone scans with T, N and the clinical stage were assessed using chi-square methods. Metastases were present in 9 patients (9%). In five of these cases, the pattern was manifestly metastatic without the need to other investigation. In the other cases, interpretation required complementary investigation. The yield of metastases was very low in localized stages, this pointed out the difficulty in interpretation of radionuclide bone scans for localized stages, probably due to a less skeletal extension.

Download full-text PDF

Source

Publication Analysis

Top Keywords

radionuclide bone
24
bone scan
12
bone scans
12
breast cancer
8
localized stages
8
radionuclide
6
bone
5
scan initial
4
initial staging
4
staging breast
4

Similar Publications

STRUCTURAL AND FUNCTIONAL BONE FEATURES IN CHILDREN RESIDING IN THE RADIOLOGICALLY CONTAMINATED TERRITORIES OF UKRAINE.

Probl Radiac Med Radiobiol

December 2024

State Institution «National Research Center of Radiation Medicine, Hematology and Oncology of the National Academy of Medical Sciences of Ukraine», 53 Yuriia Illienka Str., Kyiv, 04050, Ukraine.

Objective: Evaluation of structural features and metabolic/biochemical abnormalities of the bone tissue and relevant regulation patterns in children, residing in the radiologically contaminated territories (RCT).

Materials And Methods: Children (n = 148) aged 7 to 18 years old were involved in the study. Bone mineral density (BMD) is given in 3 grades according to the mean square deviation values, namely Grade I - standard (n = 75),Grade II - reduced (n = 45) and Grade III - very low one (n = 28).

View Article and Find Full Text PDF

Purpose: To evaluate organ-specific response to [Lu]DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) in patients with small intestine neuroendocrine tumor (SiNET) through [Ga]DOTATOC PET/CT, and to analyze tumor uptake and functional volume variations at different metastatic sites in relation to disease progression during clinical follow-up after treatment.

Methods: A retrospective analysis was conducted on 33 metastatic patients. PET/CT were performed pre-treatment (PET0), mid-treatment after two PRRT cycles (PET2), and post-treatment (PET4).

View Article and Find Full Text PDF

Influence of dosimetry accuracy on the correlation with treatment outcome in a preliminary PSMA radiopharmaceutical therapy study.

Eur J Nucl Med Mol Imaging

December 2024

Department of Nuclear Medicine, Inselspital, Bern University Hospital, University of Bern, Freiburgstrasse 20, 3010, Bern, Switzerland.

Introduction: Despite the potential of dosimetry in optimizing personalized radiopharmaceutical therapy (RPT), its limited clinical implementation impedes the development of simplified protocols for routine adoption. However, simplifications may introduce errors in dosimetry, prompting questions about their impact on clinical practice.

Materials And Methods: In this retrospective study, we analyzed data from 21 patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who underwent multiple cycles of Lu-PSMA-617 RPT treatment.

View Article and Find Full Text PDF

First preclinical SPECT/CT imaging and biodistribution of [Er]ErCl and [Er]Er-PSMA-617.

EJNMMI Radiopharm Chem

December 2024

Life Sciences Division, TRIUMF, 4004 Wesbrook Mall, Vancouver, BC, V6T 2A3, Canada.

Background: Er (t = 10.4 h, E = 47.1 keV (59.

View Article and Find Full Text PDF

Radioligand therapy is a targeted cancer treatment modality in which radioisotopes are utilized in the delivery of radiation at targeted cancer cells, with the goal of sparing normal cells. Prostate cancer is a well-known radiosensitive disease, historically treated with radioisotopes such as Strontium-89, Samarium-153, and Radium-223 for palliation of bone metastases. Recently, prostate specific membrane antigen (PSMA) has recently been employed as a radioligand target due to its unique properties of high expression on the surface of prostate cancer cells, limited expression in normal tissue, function as an internalizing cell surface receptor, and increased expression with androgen deprivation therapy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!